{"schema":"sb.node.v1","id":"sb:e/6d911ae375a0bffac4f2f4c7","kind":"entity","label":{"text":"glp-1","locale":"en"},"identity":{"anchor":"label:en:glp-1","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-29T23:27:11.436223+00:00","releaseId":"sb-9d7a5e7422f6","snapshot":"deploy 91ea3c367e4fca410148f0042e85deef49ce317f"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":572,"separatePublishers":135,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.435,"named":249,"of":572,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn only from rows whose own title or URL names the subject (the entity graph's subject gate)","blind":["only 44% of the 572 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"canonical","kind":"legacy","kindBasis":"seed","reason":"entity graph provenance 'curated'; part of the hand-written seed vocabulary that predates machine promotion; no receipt exists","policy":"promotion (seed vocabulary; no receipt)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-06","to":"2026-10-30","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.084: about 92% of mentions carry no typed assertion"]}},"dimensions":{"domains":[],"activeDays":64,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/86f44624ff958ce7237f54a2","kind":"observation","label":"The Medical News · 2026-10-29 · Thyroid cancer risks and medication timing with oral GLP-1s","url":"https://www.news-medical.net/news/20261028/Thyroid-cancer-risks-and-medication-timing-with-oral-GLP-1s.aspx","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/71ed73e7031f00deff850b31","kind":"observation","label":"2 Minute Medicine · 2026-10-29 · In topline phase 3 results, retatrutide lowered A1C more and reduced weight more than semaglutide 2 mg at 80 weeks","url":"https://www.2minutemedicine.com/in-topline-phase-3-results-retatrutide-lowered-a1c-more-and-reduced-weight-more-than-semaglutide-2-mg-at-80-weeks/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/624da2da144d52a85bf93ee9","kind":"observation","label":"Nutrition Insight · 2026-10-29 · IFF report maps GLP-1 eating moments from protein-first mornings to evening comfort","url":"https://www.nutritioninsight.com/news/iff-glp-1-eating-occasions-food-beverage-report.html","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/d32699ec36c123ad93477320","kind":"observation","label":"Nutraceutical Business Review · 2026-10-29 · IFF identifies ten consumer moments reshaping food and beverage innovation in the GLP-1 era","url":"https://nutraceuticalbusinessreview.com/iff-identifies-ten-consumer-moments-reshaping-food-and","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/ec25a92f3bcdc32719ce108b","kind":"observation","label":"Medical Daily · 2026-10-29 · GLP-1 Weight-Loss Pills Made From Peptides May Need 10 to 100 Times the Active Ingredient of a Shot, Testing Drug Manufacturing","url":"https://www.medicaldaily.com/oral-glp-1-pills-peptide-manufacturing-challenges-480540","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/508342993c308a7690e31e92","kind":"observation","label":"Clinical Trials Arena · 2026-10-28 · Vanda reports Phase III tradipitant trial data in GLP-1-associated vomiting","url":"https://www.clinicaltrialsarena.com/news/vanda-tradipitant-trial-data-glp-1-vomiting/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/95e6fca0b9b91563860f342c","kind":"observation","label":"STAT News · 2026-10-28 · STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study","url":"https://www.statnews.com/2026/10/28/biotech-news-lillys-triple-g-drug-beats-ozempic-in-head-to-head-study/?utm_campaign=rss","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/e77e97764017358f46af38e1","kind":"observation","label":"STAT News · 2026-10-28 · STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study","url":"https://www.statnews.com/2026/10/28/retatrutide-vs-ozempic-lilly-diabetes-study/?utm_campaign=rss","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/1b3991056e0bba9c6bdcc091","kind":"observation","label":"Clinical Trials Arena · 2026-10-28 · Lilly’s retatrutide beats Ozempic in head-to-head trial","url":"https://www.clinicaltrialsarena.com/news/lillys-retatrutide-beats-ozempic-in-head-to-head-trial/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/2c44fff90693537bad8c887e","kind":"observation","label":"Endpoints News · 2026-10-28 · Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes","url":"https://endpoints.news/lillys-triple-g-drug-retatrutide-outshines-novos-ozempic-in-diabetes/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}}],"cursor":"c1.eyJpZCI6InNiOmUvNmQ5MTFhZTM3NWEwYmZmYWM0ZjJmNGM3IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTI5VDIzOjI3OjExLjQzNjIyMyswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity whose own title or URL (the entity graph's subject gate) names it; each says which in match. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":12,"byKind":{"claim":2,"co-mentioned":10},"items":[{"id":"sb:p/fe4eeaa58121cb970e760687","kind":"claim","label":"Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss — corroborated","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/cdcf19517833936605ca7c38","kind":"claim","label":"Corxel US bets on SPAC route to fund oral GLP-1 race — single source","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with weight loss (215 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d151dd31bd2dd9356d1f8f4f"},{"kind":"relation","label":"co-mentioned with fda (148 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/10257615bbfa78ed1d42ee2a"},{"kind":"relation","label":"co-mentioned with eli lilly (134 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/780e192cbb11a0ba2d140505"},{"kind":"relation","label":"co-mentioned with glp-1s (132 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b7bf40cafc38451ad9cfa045"},{"kind":"relation","label":"co-mentioned with ai (106 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/dcde6980fe390fd903a1cd36"},{"kind":"relation","label":"co-mentioned with novo nordisk (85 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1be62960e6ad4da2c2b9f6cf"},{"kind":"relation","label":"co-mentioned with mounjaro (78 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/73192c912bb21678c37bcbc7"},{"kind":"relation","label":"co-mentioned with china (72 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/26019bd2ef8ead7e2f3e8ce6"}],"cursor":"c1.eyJpZCI6InNiOmUvNmQ5MTFhZTM3NWEwYmZmYWM0ZjJmNGM3IiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMC0yOVQyMzoyNzoxMS40MzYyMjMrMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/6d911ae375a0bffac4f2f4c7","mcp":"traverse {\"id\":\"sb:e/6d911ae375a0bffac4f2f4c7\"}","page":"/entity/glp-1/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/6d911ae375a0bffac4f2f4c7\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/6d911ae375a0bffac4f2f4c7\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"free-record","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/6d911ae375a0bffac4f2f4c7\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"free-record","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/6d911ae375a0bffac4f2f4c7\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"free-record","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history, which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"free-record","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"free-record","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"watch","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"watch","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"watch","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"watch","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"one-time-read","reason":"one-time Reads are not offered through this door; use ask"}]}